Search hospitals > Texas > Amarillo
PharmaTex Research
Claim this profileAmarillo, Texas 79109
Global Leader in Coronavirus
Conducts research for Cardiovascular Disease
Conducts research for Heart Failure
Conducts research for Heart Attack
Conducts research for Stroke
33 reported clinical trials
1 medical researcher
Summary
PharmaTex Research is a medical facility located in Amarillo, Texas. This center is recognized for care of Coronavirus, Cardiovascular Disease, Heart Failure, Heart Attack, Stroke and other specialties. PharmaTex Research is involved with conducting 33 clinical trials across 38 conditions. There are 1 research doctors associated with this hospital, such as David Brabham.Top PIs
Clinical Trials running at PharmaTex Research
Heart Failure
Cardiovascular Disease
Stroke
Atrial Fibrillation
Coronary Artery Disease
Hypercholesterolemia
Percutaneous Coronary Intervention
Angioplasty
Implant Site Thrombosis
Bleeding
Ziltivekimab
for Heart Failure and Inflammation
The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study is expected to last for up to 1 year and 4 months.
Recruiting1 award Phase 3
BI 690517 + Empagliflozin
for Heart Failure
This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are: * Vicadrostat/empagliflozin group: participants take vicadrostat/empagliflozin as tablets once a day. * Placebo/empagliflozin group: participants take placebo/empagliflozin as tablets once a day. Participants can stay in the study as long as they benefit from treatment and can tolerate it. During this time, they visit their doctors regularly. The doctors regularly check participants' health and take note of any unwanted effects. The study staff may also contact the participants by phone. Participants also regularly answer questions about their well-being. The study does not have a fixed duration. It continues until there is enough data to see if the treatment is working.
Recruiting1 award Phase 32 criteria
Vicadrostat + Empagliflozin
for Heart Failure
This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People can join the study if they have been diagnosed with chronic HF at least 3 months before the study. The purpose of this study is to find out whether a medicine called vicadrostat, in combination with another medicine called empagliflozin, helps people with chronic heart failure. In this study, participants are put into 2 groups randomly. Participants have an equal chance of being in either group. One group takes vicadrostat/empagliflozin tablets, and the other group takes placebo/empagliflozin tablets. Placebo tablets look like vicadrostat tablets but do not contain any medicine. Participants take the study medicines as tablets once a day for between 1 and about 3.5 years. During this time, they can continue their regular treatment for heart failure. Participants can stay in the study as long as they benefit from treatment and can tolerate it, for a maximum of about 3.5 years. During this time, they visit the study site regularly. The exact number of visits is different for each participant, depending on how long they stay in the study. The study staff may also contact the participants by phone. Participants also regularly answer questions about their well-being. The doctors document when participants experience worsening of their heart failure symptoms, must go to hospital due to heart failure, or die during the study. The time until these events are observed is compared between the treatment groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.
Recruiting1 award Phase 31 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at PharmaTex Research?
PharmaTex Research is a medical facility located in Amarillo, Texas. This center is recognized for care of Coronavirus, Cardiovascular Disease, Heart Failure, Heart Attack, Stroke and other specialties. PharmaTex Research is involved with conducting 33 clinical trials across 38 conditions. There are 1 research doctors associated with this hospital, such as David Brabham.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.